Iphase DS8201A

Maelezo mafupi:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Maelezo ya bidhaa

Lebo za bidhaa

  • Uboreshaji wa bidhaa DS - 8201a, pia inajulikana kama trastuzumab deruxtecan (t - dxd), ni antibody - Dawa ya dawa (ADC) iliyoundwa kwa ajili ya matibabu ya HER2 - saratani chanya. Inachanganya her2 - kulenga antibody ya monoclonal (sawa na trastuzumab) na topoisomerase ya nguvu mimi inhibitor (deruxtecan) kama upakiaji wa cytotoxic. Dawa hiyo inatoa chemotherapy moja kwa moja kwa seli za saratani zinazoelezea HER2, kuboresha ufanisi wakati wa kupunguza uharibifu wa seli za kawaida.
    • Jamii:
      Cathepsin
    • Bidhaa Hapana.
      015200.02
    • Saizi ya kitengo:
      200Ul, 2mg/ml
    • Tishu:
      N/A.
    • Spishi:
      N/A.
    • Hali ya uhifadhi na usafirishaji:
      Hifadhi kwa - 70 ° C. Barafu kavu iliyotolewa.

  • Zamani:
  • Ifuatayo:
  • Uteuzi wa lugha